Evidence map›Paper›PMID 38356706›Full record

ArticleJournal of Cancer2024

Identification of CDKN3 as a Key Gene that Regulates Neuroblastoma Cell Differentiation.

Alexandra Vernaza, Daniela F Cardus, Jadyn L Smith, Veronica Partridge, Amy L Baker, Emma G Lewis, Angela Zhang, Zhenze Zhao, Liqin Du

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Alexandra VernazaDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Daniela F CardusDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Jadyn L SmithDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Veronica PartridgeDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Amy L BakerDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Emma G LewisDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Angela ZhangDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Zhenze ZhaoDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Liqin DuDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.
Texas State University · US

Funding

South Texas Doctoral Bridge ProgramR25GM102783 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI OYAJOBI, BABATUNDE OLUKAYODE, WHITTEN, STEVEN T · 2013 to 2022
$3.1M
Molecular and therapeutic mechanisms of differentiation-inducing microRNA miR-506-3p in neuroblastomaR15CA249653 · NCI · TEXAS STATE UNIVERSITY · PI DU, LIQIN · 2020 to 2020
$446k
NCI NIH HHS R15 CA249653NIGMS NIH HHS R25 GM102783
6 · The paper itself

Abstract

We conducted a high-content screening (HCS) in neuroblastoma BE(2)-C cells to identify cell cycle regulators that control cell differentiation using a library of siRNAs against cell cycle-regulatory genes. We discovered that knocking down expression of cyclin dependent kinase inhibitor 3 (CDKN3) showed the most potent effect in inducing neurite outgrowth, the morphological cell differentiation marker of neuroblastoma cells. We then demonstrated that CDKN3 knockdown increased expression of neuroblastoma molecular differentiation markers, neuron specific enolase (NSE), βIII-tubulin and growth associated protein 43 (GAP43). We further showed that CDKN3 knockdown reduced expression of cell proliferation markers Ki67 and proliferating cell nuclear antigen (PCNA), and reduced colony formation of neuroblastoma cells. More importantly, we observed a correlation of high tumor CDKN3 mRNA levels with poor patient survival in the investigation of public neuroblastoma patient datasets. In exploring the mechanisms that regulate CDKN3 expression, we found that multiple strong differentiation-inducing molecules, including miR-506-3p and retinoic acid, down-regulated CDKN3 expression. In addition, we found that N-Myc promoted CDKN3 expression at the transcriptional level by directly binding to the CDKN3 promoter. Furthermore, we found that CDKN3 and two additional differentiation-regulating cell cycle proteins identified in our HCS, CDC6 and CDK4, form an interactive network to promote expression of each other. In summary, we for the first time discovered the function of CDKN3 in regulating neuroblastoma cell differentiation and characterized the transcriptional regulation of CDKN3 expression by N-Myc in neuroblastoma cells. Our findings support that CDKN3 plays a role in modulating neuroblastoma cell differentiation and that overexpression of CDKN3 may contribute to neuroblastoma progression.

Indexed as

cell cycle regulatordifferentiationdifferentiation therapyneurite outgrowthneuroblastoma

Identifiers

PMID38356706
PMCPMC10861815
OpenAlexW4390697963

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.